Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 5/2024

01-05-2024 | Melanoma | Original Paper

Unlocking the potential: phenylboronic acid as a nuclear-targeting boron agent for neutron capture therapy

Authors: Jiejian Chen, Yonghao Li, Xiaoning Gan, Chengyin Weng, Xisheng Fang, Guolong Liu

Published in: Medical Oncology | Issue 5/2024

Login to get access

Abstract

It has been proposed that boron neutron capture therapy (BNCT) holds promise as a treatment modality for melanoma. However, the effectiveness of boron agents in delivery remains a critical issue to be addressed for BNCT. To this end, phenylboronic acid, which exhibits good water solubility and low cytotoxicity similar to BPA, has been investigated as a potential nuclear-targeting boron agent. The boron concentration of phenylboronic acid was found to be 74.47 ± 12.17 ng/106 B16F10 cells and 45.77 ± 5.64 ng/106 cells in the nuclei. Molecular docking experiments were conducted to investigate the binding of phenylboronic acid to importin proteins involved in nuclear transport. The potential of phenylboronic acid to serve as a desirable nucleus-delivery boron agent for neutron capture therapy in melanoma warrants further exploration.
Literature
1.
2.
Sanad MH, Abelrahman MA, Marzook FM. Radioiodination and biological evaluation of levalbuterol as a new selective radiotracer: a β2-adrenoceptor agonist. Radiochim Acta. 2016;04(5):345–53.CrossRef
3.
Rizvi SFA, Zhang H, Mehmood S, Sanad M. Synthesis of (99m)Tc-labeled 2-Mercaptobenzimidazole as a novel radiotracer to diagnose tumor hypoxia. Transl Oncol. 2020;13(12): 100854.CrossRefPubMedPubMedCentral
4.
Sanad MH, Farag AB, Salama DH. Radioiodination and bioevaluation of rolipram as a tracer for brain imaging: In silico study, molecular modeling and gamma scintigraphy. J Labelled Comp Radiopharm. 2018;61(6):501–8.CrossRefPubMed
5.
Coghi P, Li J, Hosmane NS, Zhu Y. (2023) Next generation of boron neutron capture therapy (BNCT) agents for cancer treatment. Med Res Rev. 43:1809
6.
Dymova MA, Taskaev SY, Richter VA, Kuligina EV. Boron neutron capture therapy: Current status and future perspectives. Cancer Commun (Lond). 2020;40(9):406–21.CrossRefPubMed
7.
Wang LW, Liu YH, Chou FI, Jiang SH. Clinical trials for treating recurrent head and neck cancer with boron neutron capture therapy using the Tsing-Hua Open Pool Reactor. Cancer Commun (Lond). 2018;38(1):37.PubMed
8.
Hirose K, Konno A, Hiratsuka J, et al. Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan ((10)B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial. Radiother Oncol. 2021;155:182–7.CrossRefPubMed
9.
10.
11.
Barth RF, Mi P, Yang W. Boron delivery agents for neutron capture therapy of cancer. Cancer Commun (Lond). 2018;38(1):35.PubMed
12.
Barth RF, Coderre JA, Vicente MG, Blue TE. Boron neutron capture therapy of cancer: current status and future prospects. Clin Cancer Res. 2005;11(11):3987–4002.CrossRefPubMed
13.
Hartman T, Carlsson J. Radiation dose heterogeneity in receptor and antigen mediated boron neutron capture therapy. Radiother Oncol. 1994;31(1):61–75.CrossRefPubMed
14.
Li S, Hou X, Ma Y, Wang Z. Phenylboronic-acid-based functional chemical materials for fluorescence imaging and tumor therapy. ACS Omega. 2022;7(3):2520–32.CrossRefPubMedPubMedCentral
15.
Wang R, Yin C, Liu C, et al. Phenylboronic acid modification augments the lysosome escape and antitumor efficacy of a cylindrical polymer brush-based prodrug. J Am Chem Soc. 2021;143(49):20927–38.CrossRefPubMed
16.
Chen J, Dai Q, Yang Q, et al. Therapeutic nucleus-access BNCT drug combined CD47-targeting gene editing in glioblastoma. J Nanobiotechnology. 2022;20(1):102.CrossRefPubMedPubMedCentral
17.
Wang J, Wu W, Zhang Y, et al. The combined effects of size and surface chemistry on the accumulation of boronic acid-rich protein nanoparticles in tumors. Biomaterials. 2014;35(2):866–78.CrossRefPubMed
18.
19.
Chen J, Yang Q, Liu M, et al. Remarkable Boron Delivery Of iRGD-modified polymeric nanoparticles for boron neutron capture therapy. Int J Nanomedicine. 2019;14:8161–77.CrossRefPubMedPubMedCentral
20.
Metadata
Title
Unlocking the potential: phenylboronic acid as a nuclear-targeting boron agent for neutron capture therapy
Authors
Jiejian Chen
Yonghao Li
Xiaoning Gan
Chengyin Weng
Xisheng Fang
Guolong Liu
Publication date
01-05-2024
Publisher
Springer US
Keywords
Melanoma
Melanoma
Published in
Medical Oncology / Issue 5/2024
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-024-02351-3

Other articles of this Issue 5/2024

Medical Oncology 5/2024 Go to the issue

Original Paper

Coadministration of doxorubicin with vitamin D3, Lactobacillus acidophilus, and Lactobacillus casei in the 4T1 mouse model of breast cancer: anticancer and enteroprotective effects

Original Paper

Citalopram, an antipsychotic agent, induces G1/G0 phase cell cycle arrest and promotes apoptosis in human laryngeal carcinoma HEP-2 cells

Original Paper

The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma

Review Article

Potential role of immune cell therapy in gynecological cancer and future promises: a comprehensive review

Original Paper

YWHAG promotes colorectal cancer progression by regulating the CTTN-Wnt/β-catenin signaling axis

Original Paper

Combination of IFN-gamma with STING agonist and PD-1 immune checkpoint blockade: a potential immunotherapy for gastric cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits